InnoCare Pharma Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InnoCare Pharma Ltd.
November negotiations in China over the prices of 67 new drugs have resulted in record price cuts, averaging around 62% overall and 65% for anti-tumor products. But the sting is alleviated by the prospect of substantial volume increases.
In a new landmark, Chinese firm BeiGene has posted greater quarterly sales of its cancer drug Brukinsa in the US than in China for the first time. Meanwhile, a growing number of innovative products developed in China are on the cusp of expansion into overseas markets.
Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.
With the virtual doors about to close on the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, Scrip takes a look at some of the highlights, including data for Merck KGaA and Sanofi’s new BTK inhibitors and research showing the impact of MS therapies on COVID-19 vaccine response.
- Other Names / Subsidiaries
- Beijing InnoCare Pharma Tech Co., Ltd.